Dementia, Alzheimer's, & Anavex I The Feed

preview_player
Показать описание
Paul has early-onset dementia. The drug Anavex is on trial in Melbourne, which may possibly cure Alzheimer's, the most common type of dementia.

  1. SBS The Feed
  2. SBS2
  3. SBS
  4. The Feed
  5. Marc Fennell
  6. Alzheimer's Disease (Disease Or Medical Condition)
Рекомендации по теме
Dementia, Alzheimer's, & 0:07:15

Dementia, Alzheimer's, & Anavex I The Feed

Harald Hampel, MD, 0:01:26

Harald Hampel, MD, PhD, MA, MSc: Phase IIa Study of ANAVEX 2-73 in Treatment of Alzheimer Disease

Potential breakthrough: New 0:03:01

Potential breakthrough: New treatment for Alzheimer's

Harald Hampel, MD, 0:02:10

Harald Hampel, MD, PhD, MA, MSc: Genomic Analysis of ANAVEX 2-73 in Alzheimer Disease Study

Anavex Reports Encouraging/Confusing 0:34:30

Anavex Reports Encouraging/Confusing Alzheimer's Data | Investing Springer

Spirit of the 0:18:27

Spirit of the Coast Analytics & Anavex ($AVXL) - An Introduction

New Alzheimer’s treatment 0:00:27

New Alzheimer’s treatment could become available in Australia next year

4th Annual ALS 0:11:35

4th Annual ALS ONE Research Symposium - Presentation by Nell Rebowe of Anavex Life Sciences

New treatment offering 0:01:35

New treatment offering hope for Alzheimer's patients

Update on Alzheimer's 1:06:28

Update on Alzheimer's Disease Research

Alzheimer's clinical trial 0:01:00

Alzheimer's clinical trial drug yields negative result

EARLY ALZHEIMER’S UNDERTREATMENT 0:01:34

EARLY ALZHEIMER’S UNDERTREATMENT

A Journey Through 0:20:58

A Journey Through Alzheimer's 2022

New Alzheimer's drug 0:00:24

New Alzheimer's drug shows big promise

Perspectives on the 1:16:08

Perspectives on the Alzheimer’s Disease Continuum

New dementia drugs 0:58:16

New dementia drugs and therapies: What Canadians should know

Health Beat Alzheimer 0:02:24

Health Beat Alzheimer Drug

Spirit of the 0:31:15

Spirit of the Coast Analytics' Overview of Cassava's Phase 2 Alzheimer's Data

Clinical Trial: Simufilam 0:02:54

Clinical Trial: Simufilam for Alzheimer's Disease (NCT05026177)

The Problem of 0:33:31

The Problem of Alzheimer's: Dr. Karlawish

Interview with Dr. 0:58:19

Interview with Dr. Timo Grimmer (Advisor, Anavex Life Sciences Corporation)

Harald Hampel, MD, 0:02:49

Harald Hampel, MD, PhD, MA, MSc on Advancements and Challenges in the Alzheimer Space

ANAVEX: Blarcamesine modtager 0:21:18

ANAVEX: Blarcamesine modtager EMA-ansøgningsgodkendelse til behandling af Alzheimers sygdom

FDA narrows patient 0:01:17

FDA narrows patient group for Biogen's Alzheimer's drug